Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ)

Neuromuscular Disorders

Volumn 20, Issue 5, 2010, Pages 310-318

  Hermans, Mieke C E ^a   Faber, Catharina G ^a   De Baets, Marc H ^b,c   de Die Smulders, Christine E M ^a   Merkies, Ingemar S J ^a,d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c HASSELT UNIVERSITY   (Belgium)

^d N   (Netherlands)

Author keywords

Myotonic dystrophy type 1; Outcome assessment; Rasch analysis

Indexed keywords

ADULT; AGED; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ACTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RASCH ANALYSIS; TEST RETEST RELIABILITY;

ADOLESCENT; ADULT; AGED; BIAS (EPIDEMIOLOGY); DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYOTONIC DYSTROPHY; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77952010636     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.03.010     Document Type: Article

References (49)

1. Harper P.S. Myotonic dystrophy 2001, Saunders, London.
2. Harley H.G., Rundle S.A., MacMillan J.C., Myring J., Brook J.D., Crow S., et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993, 52:1164-1174.
3. Natterlund B., Gunnarsson L.G., Ahlstrom G. Disability, coping and quality of life in individuals with muscular dystrophy: a prospective study over five years. Disabil Rehabil 2000, 22:776-785.
4. Bostrom K., Natterlund B.S., Ahlstrom G. Sickness impact in people with muscular dystrophy: a longitudinal study over 10 years. Clin Rehabil 2005, 19:686-694.
5. Gagnon C., Mathieu J., Jean S., Laberge L., Perron M., Veillette S., et al. Predictors of disrupted social participation in myotonic dystrophy type 1. Arch Phys Med Rehabil 2008, 89:1246-1255.
6. Antonini G., Soscia F., Giubilei F., De Carolis A., Gragnani F., Morino S., et al. Health-related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. J Rehabil Med 2006, 38:181-185.
7. Wheeler T.M., Thornton C.A. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007, 20:572-576.
8. Wheeler T.M. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008, 5:592-600.
9. Wheeler T.M., Sobczak K., Lueck J.D., Osborne R.J., Lin X., Dirksen R.T., et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (New York, NY) 2009, 325:336-339.
10. Aaronson N.K. Quality of life: what is it? How should it be measured?. Oncology (Williston Park) 1988, 2:69-76. 64.
11. World Health Organization. International classification of functioning, disability and health. Geneva, 2001.
12. Mathieu J., De Braekeleer M., Prévost C., Boily C. Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation. Neurology 1992, 42:203-208.
13. Orndahl G., Grimby G., Grimby A., Johansson G., Wilhelmsen L. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. J Intern Med 1994, 235:205-210.
14. Jaspert A., Fahsold R., Grehl H., Claus D. Myotonic dystrophy: correlation of clinical symptoms with the size of the CTG trinucleotide repeat. J Neurol 1995, 242:99-104.
15. Lindeman E., Leffers P., Spaans F., Drukker J., Reulen J., Kerckhoffs M., et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil 1995, 76:612-620.
16. Walter M.C., Reilich P., Lochmuller H., Kohnen R., Schlotter B., Hautmann H., et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol 2002, 249:1717-1722.
17. Berard C., Payan C., Hodgkinson I., Fermanian J. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 2005, 15:463-470.
18. Gagnon C., Mathieu J., Noreau L. Measurement of participation in myotonic dystrophy: reliability of the LIFE-H. Neuromuscul Disord 2006, 16:262-268.
19. Streiner D.L., Norman G.R. Health measurement scales. A practical guide to their development and use 1995, Oxford University Press, New York.
20. Mathieu J., Boivin H., Meunier D., Gaudreault M., Bégin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001, 56:336-340.
21. DeVellis R.F. Classical test theory. Med Care 2006, 44:S50-S59.
22. Stucki G., Daltroy L., Katz J.N., Johannesson M., Liang M.H. Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 1996, 49:711-717.
23. Rasch G. Probalilistic models for some intelligence and attainment tests 1980, University of Chicago Press, Chicago.
24. Bond T.G., Fox C.M. Applying the Rasch model: fundamental measurement for the human sciences 2001, Lawrence Erlbaum Associates, New York.
25. Pallant J.F., Tennant A. An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 2007, 46:1-18.
26. Vandervelde L., van den Bergh P.Y.K., Goemans N., Thonnard J.L. ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord 2007, 17:459-469.
27. Bombardier C., Tugwell P. A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol 1982, 9:753-757.
28. Wright B.D., Stone M.H. Best test design 1979, Mesa Press, Chicago.
29. Medical Research Council. In: Aids to the examination of the peripheral nervous system. London: Her Majesty's Stationary Office; 1943. p. 1-2.
30. Kleyweg R.P., van der Meche F.G., Schmitz P.I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 1991, 14:1103-1109.
31. Andrich D, Lyne A, Sheridan B, Luo G. RUMM 2020. RUMM Laboratory, Perth, 2003.
32. Linacre J.M. Sample size and item calibration stability. Rasch Measure Trans 1994, 7:28.
33. Altman D.G. Practical statistics for medical research 1991, Chapman and Hall, London.
34. Fisher W.P. Reliability statistics. Rasch Measure Trans 1992, 6:238.
35. Dorans N.J., Holland P.W. DIF detection and description: Mantel-Haenszel and standardisation. Differential item functioning 1993, 36-66. Lawrence Erlbaum Associates, Hillsdale: Lawrence Erlbaum Associates. P.W. Holland, H. Wainer (Eds.).
36. Embretson S.E., Reise S.P. Item response theory for psychologists 2000, Lawrence Erlbaum Associates, New Jersey.
37. Tennant A., Conaghan P.G. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper?. Arthritis Rheum. 2007, 57:1358-1362.
38. Herndon J.E., Harrell F.E. The restricted cubic spline hazard model. Commun Stat Theory Methods 1990, 639-663.
39. Bland J.M., Altman D.G. Multiple significance tests: the Bonferroni method. BMJ 1995, 310:170.
40. Sloan J., Symonds T., Vargas-Chanes D., Fridley B. Practical guidelines for assessing the clinical significance of health related quality of life within clinical trials. Drug Inf J 2003, 37:23-31.
41. Merkies I.S., Schmitz P.I., van der Meche F.G., Samijn J.P., van Doorn P.A. Connecting impairment, disability, and handicap in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2003, 74:99-104.
42. Laberge L., Bégin P., Montplaisir J., Mathieu J. Sleep complaints in patients with myotonic dystrophy. J Sleep Res 2004, 13:95-100.
43. Ronnblom A., Forsberg H., Danielsson A. Gastrointestinal symptoms in myotonic dystrophy. Scand J Gastroenterol 1996, 31:654-657.
44. Kalkman J.S., Schillings M.L., van der Werf S.P., Padberg G.W., Zwarts M.J., van Engelen B.G., et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry 2005, 76:1406-1409.
45. van Engelen B.G., Eymard B., Wilcox D. 123rd ENMC International Workshop: management and therapy in myotonic dystrophy, 6-8 February 2004, Naarden, The Netherlands. Neuromuscul Disord 2005, 15:389-394.
46. Hughes R.A., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008, 7:136-144.
47. van der Meche F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992, 326:1123-1129. Dutch Guillain-Barre Study Group.
48. Liang M.H. Evaluating measurement responsiveness. J Rheumatol 1995, 22:1191-1192.
49. Jaeschke R., Singer J., Guyatt G.H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989, 10:407-415.